试验注册
评估HW243040在健康受试者中的安全性、耐受性、药代动力学和药效学的研究
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HW243040 in Healthy Participants
作者：The Third Xiangya Hospital of Central South University
ClinicalTrials.gov · 2026年9月25日 · The Third Xiangya Hospital of Central S…
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要）…
已等待 0 秒大约需要 10–20 秒
可以先看别的，做好了会自动出现在这里。
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。
摘要Abstract
Brief summary: This is a Phase I, randomized, double-blind, placebo-controlled, single-center, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HW243040 in healthy participants. The study consists of two parts: Part A (Single Ascending Dose, SAD) and food effect study, and Part B (Multiple Ascending Dose, MAD). A total of approximately 98 healthy participants will be enrolled.
Conditions: Healthy Volunteers
Interventions: drug: HW243040; drug: HW243040 Matching Placebo
Phase: Phase 1
Enrollment: 98 (estimated)
Sponsor: The Third Xiangya Hospital of Central South University (other)
Status: not yet recruiting
还没有查过关联研究
我会去找这篇研究之前的基础工作、做类似事情的研究，以及之后引用它的研究，并说明每篇为什么相关。